2460 results about "Headaches" patented technology

Disclosed are devices and methods for detecting, preventing, and/or treating neurological disorders. These devices and methods utilize electrical stimulation, and comprise a unique concentric ring electrode component. The disclosed methods involve the positioning of multiple electrodes on the scalp of a mammal; monitoring the mammal's brain electrical patterns to identify the onset of a neurological event; identifying the location of the brain electrical patterns indicative of neurological event; and applying transcutaneous or transcranial electrical stimulation to the location of the neurological event to beneficially modify brain electrical patterns. The disclosed methods may be useful in the detection, prevention, and/or treatment of a variety of indications, such as epilepsy, Parkinson's Disease, Huntington's disease, Alzheimer's disease, depression, bipolar disorder, phobia, schizophrenia, multiple personality disorder, migraine or headache, concussion, attention deficit hyperactivity disorder, eating disorder, substance abuse, and anxiety. The disclosed methods may also be used in combination with other peripheral stimulation techniques.

An expansible ear canal insert for treating TMJ disorders and headaches which acts directly on the TMJ and associated ligament and muscle structures to reduce stress and loads placed on the articulator disc located between the temporal bone and the mandible, as well as supportive muscles and ligaments near the TMJ. The insert is adapted to expand by application of body heat. In the expanded condition, the insert provides support to the TMJ and associated ligament and muscle structures.

The present invention provides novel methods and compositions for the treatment and prevention of headaches, vascular headaches, migraine headaches, cluster headaches, and migraine. One of the headaches, vascular headaches, migraine headaches, cluster headaches, and migraine treated by the methods and compositions of the invention is migraine.

Disclosed are methods and systems for non-invasive neuromodulation of the Sphenopalatine Ganglion and associated neural structures vidian nerve and/or sphenopalatine nerve using an ultrasound transducer to treat migraine and cluster headaches as well as other indications such as neurologic and psychiatric conditions. Treatment may be unilateral or bilateral.

The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.

A method of treatment or prevention of headache, migraine or cluster headaches, which method comprises co-administration of a therapeutically effective amount of the compound 1-[N<2>-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine[BIBN4096BS] or a physiologically acceptable salt thereof and a therapeutically effective amount of a second active antimigraine drug, particularly sumatriptan, zolmitriptan or dihydroergotamin or a physiologically acceptable salt thereof, as well as to the corresponding pharmaceutical compositions and the preparation thereof.

This invention provides compositions, methods and process of producing extracts and pure compounds from Xanthoceras sorbifolia. The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, kidney disorder, and impotence; for improving cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's, cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, headache, dizziness, kidney disorder. This invention provides compounds of oleanene triterpenoidal saponin in nature with the characteristics that at least one angeloyl group attache to Carbon 21 or/and 22, or/and linked to the sugar. The compounds of the present invention have various pharmaceutical and therapeutic applications.

Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.

The invention relates to a sally quinquefolia tea for reducing blood pressure, blood lipid and blood glucose, and is characterized in that the sally quinquefolia tea is mainly prepared from the following compositions in weight proportions : 250 to 300 portions of tea leaves, 5 to 10 portions of ginseng leaves, 3 to 6 portions of apocynum venetum (leaves), 3 to 6 portions of mulberry leaves, 3 to 6 portions of eucommia leaves, 3 to 6 portions of ginkgo leaves and 5 to 10 portions of ganoderma. The sally quinquefolia tea for reducing blood pressure, blood lipid and blood glucose is prepared scientifically with proper preparation, wherein in the blood pressure reduction aspect, the headache, dizziness and giddiness can be prevented; in the blood lipid reduction aspect, the palpitation, fatigue and bad sleep can be prevented; and in the blood glucose reduction aspect, the thirsty, emaciation and more night urine are prevented so as to prevent serious complicating diseases to the brain, the heart and the kidney. The sally quinquefolia tea has the functions of medicine, so that the health care function is obvious, colour, aroma and flavor of the original tea leaf are maintained with mellow scent, pure and sweet taste. Therefore, the sally quinquefolia tea is the best health-care functional drink for reducing blood pressure, blood lipid and blood glucose and is suitable for people who need to prevent and treat angiocardiopathy.

The invention specifies a method and system for leading a person suffering from “sympathetic predominance”, a specific symptom of which is “hypertension”, to breathe according to a certain pattern for the express purpose of positively altering the condition of sympathetic predominance (over activation), having the effect of bringing the autonomic nervous system into the state of balance, with consequent reductions in “tenseness”, blood pressure, muscular tightness, and emotional strain, as well as the alleviation of the myriad of subtle neuro-physiological consequences resulting from sympathetic predominance potentially including headaches, anxiety, sleep disorders, allergies, and other maladies that have yet to be attributed to this condition, thus leading to a general improvement in health, well being, and homeostasis. It accomplishes this by systematically reducing the breathing frequency with consequent increases in breathing depth, the ultimate goal being the realization and ongoing maintenance of 1 complete breathing cycle in 11.76 seconds or 5 complete breathing cycles in 58.8 seconds, the result being improved health, well being, and homeostasis.

The present invention relates to compounds of Formula (I)

as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and/or function, removing body fat and/or cellulite, treating cancer, treating viral infections and others. A hostile biophysical environment may also be used in conjunction with systems and methods for increasing local blood flow, according to one set of embodiments. For example, by using a nitric oxide donor such as L-arginine, local blood flow may be increased, e.g., by transdermally delivering the nitric oxide precursor. The nitric oxide donor may be the sole cause of increased blood flow, or it may be supplemented with an adjunct such as theophylline.

The invention discloses a new Chinese medicinal composition for treating medial headache and migraine and a preparation method thereof. The Chinese medicinal composition comprises the following raw material medicaments: szechuan lovage rhizome, root of red-rooted salvia, costustoot, fenugreek lysimachia, benzoin, tangerine peel, radix curcumae, cyperus rotunus, golden thread, baical skullcap root, cassia twig, incised notopterygium rhizome, angelica dahurlica, kudzuvine root, peach seed, safflower, common burreed rhizome, zedoary, pangolin scales, raw astragalus, radix paeoniae alba, red paeony root, tall gastrodia tuber, gambir plant, storax, grassleaf sweelflag rhizome, fineleaf schizonepeta herb, divaricate saposhnikovia root, radix ephedrae, weeping forsythia, manchurian wildginger, biond magnolia flower, mentha haplocalyx, raw rehmannia root, szechwan chinaberry fruit, rose, radix pseudo-ginseng, rosewood heart wood, garden burnet root, leonurus heterophyllus, cowherb seed, ground beeltle, sappan wood, dragon's blood, pinellia tuber and the like. The Chinese medicinal composition can be prepared into any oral administration preparation used commonly according to the conventional method of Chinese medicinal preparations. The Chinese medicinal composition can improve headaches of bitamporal, foreheads and orbital parts, pulsatile headache or boring pain and the like, and associated symptoms of nausea, vomiting, blurred vision, frequent micturition, urination disorder, stuffy nose, palpitation, hypertension, hypotension, arrhythmia, megrim, ataxia, diplopia, hearing loss, tinnitus, disturbance of consciousness and the like obviously, and has definite clinical effects, obvious curative effect and quick response. The Chinese medicinal composition of the invention is combined by adopting medicinal and edible medicaments formulated by National Formulary basically, and thus, the Chinese medicinal composition has the advantages of low cost and no toxic or side effect.

The present invention provides compositions, methods and kits for treating, preventing or reducing the risk of developing a CNS disorder. In general, the invention involves utilizing caffeine for preventing or alleviating pathological symptoms of a CNS disorder, such as headache, epilepsy, pain, Parkinson's disease, psychiatric disorders such as anxiety, bipolar disorder, depression, and schizophrenia, ADD, and ADHD.

A method of treating headache is provided using a water soluble magnesium salt. Specifically, a method of treating a headache is provided for an individual having a serum ionized magnesium concentration of 0.44 mmoles/L to 0.53 mmoles/L and having at least one headache symptom by administering an amount of a water soluble magnesium salt sufficaent to inhibit at least one headache symptom in the individual within 24 hours and to raise the serum ionized magnesium concentration in the individual to within a normal ionized magnesium concentration range of 0.54 mmoles/L to 0.67 mmoles/L. Headache symptoms which may be inhibited include: pain, aura, photophobia, nausea, unilateral pain and phonophobia.

Electrical-stimulation device with gel-dispensing kit, and a method of making and using the parts of the kit. A convenient and easy-to-use system to provide an electrically conductive path from a transcutaneous electrical nerve stimulation (TENS) device to the skin surface of a patient to supply transcutaneous stimulation, even through hair. The invention provides improved prevention and treatment for headache, depression, alertness, attention deficit hyperactivity disorder (ADHD), epilepsy, anxiety, post-traumatic stress disorder (PTSD), and behavioral and/or other disorders. Some embodiments provide a headache-treatment system that includes an electrode base shaped to conform to a back of a human head; a TENS having projecting spring electrodes each connected to the electrode base; means for holding an electrically conductive gel in a plurality of sealed pockets; and means for unsealing the means for holding the gel and applying the gel substantially simultaneously to the projecting spring electrodes.

A system and method that utilizes a massaging apparatus specifically for a person's temples with the expressed purpose of providing relaxation and headache relief, is herein disclosed. The apparatus is configured as a headband with battery-powered massagers at the temples. The apparatus is supported both with minimal elasticity from the headband and with ear supports. Power is supplied to the massagers from a rechargeable battery pack that can be worn about the arm or alternately the waist and is electrically tethered to the headband. Each small disc-shaped temple massager is separately powered by a small motor that produces the massaging effect which is intended to reproduce the sensation of rubbing/massaging the temples.

A once-a-day oral milnacipran pulsatile release composition has been developed that releases the drug in spaced apart “pulses”. The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. This dosage form provides in vivo drug plasma levels characterized by C_max below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml. The composition provides pulsatile release of milnacipran to produce a therapeutic effect over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.